Kobayashi Pharmaceutical Co., Ltd.
KBYPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $165,600 | $173,455 | $166,258 | $155,252 |
| % Growth | -4.5% | 4.3% | 7.1% | – |
| Cost of Goods Sold | $77,997 | $77,079 | $73,927 | $66,478 |
| Gross Profit | $87,603 | $96,376 | $92,331 | $88,774 |
| % Margin | 52.9% | 55.6% | 55.5% | 57.2% |
| R&D Expenses | $9,109 | $9,004 | $8,327 | $7,522 |
| G&A Expenses | $5,160 | $29,869 | $5,024 | $5,200 |
| SG&A Expenses | $22,029 | $57,611 | $31,608 | $31,790 |
| Sales & Mktg Exp. | $16,869 | $27,742 | $26,584 | $26,590 |
| Other Operating Expenses | $31,605 | $3,981 | $25,722 | $23,390 |
| Operating Expenses | $62,743 | $70,596 | $65,657 | $62,702 |
| Operating Income | $24,860 | $25,780 | $26,669 | $26,065 |
| % Margin | 15% | 14.9% | 16% | 16.8% |
| Other Income/Exp. Net | -$10,946 | $1,779 | $1,280 | $1,570 |
| Pre-Tax Income | $13,914 | $27,559 | $27,950 | $27,636 |
| Tax Expense | $3,842 | $7,221 | $7,927 | $7,920 |
| Net Income | $10,067 | $20,338 | $20,022 | $19,715 |
| % Margin | 6.1% | 11.7% | 12% | 12.7% |
| EPS | 135.42 | 268.16 | 259.63 | 252.36 |
| % Growth | -49.5% | 3.3% | 2.9% | – |
| EPS Diluted | 135.42 | 268.16 | 259.59 | 252.36 |
| Weighted Avg Shares Out | 74 | 76 | 77 | 78 |
| Weighted Avg Shares Out Dil | 74 | 76 | 77 | 78 |
| Supplemental Information | – | – | – | – |
| Interest Income | $207 | $214 | $85 | $131 |
| Interest Expense | $28 | $29 | $18 | $18 |
| Depreciation & Amortization | $8,022 | $6,057 | $5,358 | $4,835 |
| EBITDA | $21,964 | $33,645 | $31,864 | $30,786 |
| % Margin | 13.3% | 19.4% | 19.2% | 19.8% |